BenchSci
BenchSci's flagship product is EMET, an agentic research environment for preclinical R&D. It reasons over a knowledge graph built from 38M+ publications. Earlier products included the ASCEND platform and antibody and reagent search. It sells enterprise software subscriptions to large pharma and biotech firms, including multi-year deals with Merck and argenx (2026) and a Google Cloud infrastructure partnership (Aug 2026). Founded in 2015, it raised a US$70M (C$95M) Series D in 2023 led by Generation Investment Management, bringing total funding to about C$218M (US$170M).
Funding
Every round, secondary, debt facility or acquisition involving BenchSci that AI Lounge tracks, newest first.
No rounds recorded yet.
Members see every AI company on AI Lounge with revenue, funding, valuation and investors, searchable and sortable, free.
Create my free account →Log in